Literature DB >> 35064523

Application of Parametric Shared Frailty Models to Analyze Time-to-Death of Gastric Cancer Patients.

Mesfin Esayas Lelisho1, Geremew Muleta Akessa2, Demeke Kifle Demissie2, Samuel Fikadu Yermosa2, Solomon Abebaw Andargie3, Seid Ali Tareke3, Digvijay Pandey4.   

Abstract

BACKGROUND: Despite its declining incidence, gastric cancer (GC) is one of the world's leading malignancies and a major global health concern due to its high prevalence and fatality rate. Furthermore, it is the world's fourth most common cancer and the second leading cause of cancer death. Studying the determinants of time to death of gastric cancer patients will give clinicians more information to develop specific treatment plans, forecast prognosis, and track the progress of death cases. The application of the frailty model can help account for random variation in survival that may exist due to unobserved factors, as well as show the impact of latent factors on death risk. As a result, the purpose of this study was to assess the determinants of time to death of GC patients' by applying the parametric shared frailty models.
METHODS: The data for this study were obtained from gastric cancer patients admitted to the Tikur Anbesa Specialized Hospital, Addis Ababa, from January 1, 2015, to February 29, 2020. With the aim of coming up with an appropriate survival model that determines factors that affect the time to death of gastric cancer patients, various parametric shared frailty models were compared. In all of the frailty models, patient regions were used as a clustering variable. The current study implemented exponential, Weibull, log-logistic, and lognormal distributions for baseline hazard functions with gamma and inverse Gaussian's frailty distributions. The performance of all models was compared using the AIC and BIC criteria. R statistical software was used to conduct the analysis.
RESULTS: A retrospective study was undertaken on a total of 407 gastric cancer patients under follow-up at Tikur Anbesa Specialized Hospital. Of all 407 GC patients, 56.3% died while the remaining 43.7% were censored. The patients' median time to death was 21.9 months, with a maximum survival time of 49.6 months. In the current study, the clustering effect was significant in modeling the time to death from gastric cancer. The Weibull model with inverse Gaussian frailty has the minimum AIC and BIC value among the candidate models compared. The dependency within the clusters for the Weibull-inverse Gaussian frailty model was [Formula: see text] (13.4%). According to the results of our best model (Weibull-inverse Gaussian), the sex of the patient, the smoking status, the tumor size, the treatment taken, the vascular invasion, and the disease stage was found to be statistically significant at an alpha = 0.05 significance level.
CONCLUSION: Time to death of GC patient's data set was well described by the Weibull-inverse Gaussian shared frailty. Furthermore, Weibull baseline distribution best fits the GC data set as it enables proportional hazard and accelerated failure time model, for time to failure data. There is unobserved heterogeneity between clusters (patient regions), indicating the need to account for this clustering effect. In this study, survival time to death among GC patients was discovered to be small. Covariates like older age, being male, having higher (advanced) stage of GC disease (stage three and stage four), advanced tumor size, being smoker, infected by Helicobacter pylori, and existence of vascular invasion significantly accelerate the time to death of GC patients. In contrast, talking combination of more treatments prolongs the time to death of patients. To improve the health of patients, interventions should be taken based on significant prognostic factors, with special attention dedicated to patients with such factors to prevent GC death.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Gastric cancer; Heterogeneity; Parametric shared frailty model; Survival analysis

Year:  2022        PMID: 35064523     DOI: 10.1007/s12029-021-00775-y

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  36 in total

1.  Shared parameter models for the joint analysis of longitudinal data and event times.

Authors:  Edward F Vonesh; Tom Greene; Mark D Schluchter
Journal:  Stat Med       Date:  2006-01-15       Impact factor: 2.373

2.  A joint frailty model for survival and gap times between recurrent events.

Authors:  Xuelin Huang; Lei Liu
Journal:  Biometrics       Date:  2007-06       Impact factor: 2.571

Review 3.  Frailty models for survival data.

Authors:  P Hougaard
Journal:  Lifetime Data Anal       Date:  1995       Impact factor: 1.588

Review 4.  Risk factors for rising incidence of esophageal and gastric cardia adenocarcinoma.

Authors:  Jacquelyn S Carr; Syed F Zafar; Nabil Saba; Fadlo R Khuri; Bassel F El-Rayes
Journal:  J Gastrointest Cancer       Date:  2013-06

Review 5.  Gastric cancer.

Authors:  Eric Van Cutsem; Xavier Sagaert; Baki Topal; Karin Haustermans; Hans Prenen
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

Review 6.  Individual risk stratification of gastric cancer: evolving concepts and their impact on clinical practice.

Authors:  Massimo Rugge; Lisette G Capelle; Matteo Fassan
Journal:  Best Pract Res Clin Gastroenterol       Date:  2014-09-28       Impact factor: 3.043

7.  Clinicopathologic study of node-negative advanced gastric cancer and analysis of factors predicting its recurrence and prognosis.

Authors:  Hsu-Huan Chou; Chia-Jung Kuo; Jun-Te Hsu; Tsung-Hsing Chen; Chun-Jun Lin; Jeng-Hwei Tseng; Ta-Sen Yeh; Tsann-Long Hwang; Yi-Yin Jan
Journal:  Am J Surg       Date:  2012-10-01       Impact factor: 2.565

8.  Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer.

Authors:  Masanori Tokunaga; Yutaka Tanizawa; Etsuro Bando; Taiichi Kawamura; Masanori Terashima
Journal:  Ann Surg Oncol       Date:  2012-10-18       Impact factor: 5.344

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer.

Authors:  Kousuke Hashimoto; Keishiro Aoyagi; Taro Isobe; Kikuo Kouhuji; Kazuo Shirouzu
Journal:  Gastric Cancer       Date:  2013-04-05       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.